Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best hot stocks to buy according to analysts. On February 19, Praxis Precision Medicines reported the financial results for Q4 2025, ending 2025 with $926 million in cash & investments. Following an additional $621 million financing in January, the company’s cash runway is now expected to fund operations into 2028. While R&D expenses rose to $267.1 million for the full year due to intensified clinical activity, the company has also expanded its leadership team and Board of Directors to support its upcoming commercial launches and long-term clinical strategy.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) submitted two NDAs to the FDA for ulixacaltamide, aimed at treating essential tremor, and relutrigine, for specific pediatric epileptic encephalopathies. Both therapies have received Breakthrough Therapy Designation, with ulixacaltamide notably being the first investigational therapy to show positive Phase 3 results for essential tremor.

The company is advancing several high-potential programs through its Cerebrum and Solidus platforms. Vormatrigine, a potent sodium-channel modulator for epilepsy, is expected to yield Phase 3 topline results in Q2 2026, while the antisense oligonucleotide elsunersen is on track for Phase 1/2 results in H1 2026. Beyond its late-stage assets, Praxis Precision Medicines intends to nominate three new development candidates by mid-2026 to address conditions such as autism spectrum disorders and intellectual disabilities, with regulatory submissions planned for the next two years.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company that develops therapies for central nervous system/CNS disorders characterized by neuronal excitation-inhibition imbalance in the US.

While we acknowledge the potential of PRAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.